GH Research Plc (GHRS)
28.23
+0.31
(+1.11%)
USD |
NASDAQ |
Sep 04, 16:00
28.24
0.00 (0.00%)
Pre-Market: 20:00
GH Research Research and Development Expense (Quarterly) : 12.40M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.40M |
| March 31, 2026 | 12.38M |
| December 31, 2025 | 11.38M |
| September 30, 2025 | 10.56M |
| June 30, 2025 | 8.951M |
| March 31, 2025 | 7.846M |
| December 31, 2024 | 8.201M |
| September 30, 2024 | 8.392M |
| June 30, 2024 | 9.75M |
| March 31, 2024 | 8.652M |
| December 31, 2023 | 8.244M |
| Date | Value |
|---|---|
| September 30, 2023 | 7.08M |
| June 30, 2023 | 7.166M |
| March 31, 2023 | 7.296M |
| December 31, 2022 | 6.899M |
| September 30, 2022 | 4.613M |
| June 30, 2022 | 4.24M |
| March 31, 2022 | 4.714M |
| December 31, 2021 | 3.351M |
| September 30, 2021 | 2.551M |
| June 30, 2021 | 1.954M |
| March 31, 2021 | 0.692M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Atai Beckley, Inc. | 28.07M |
| Avadel Pharmaceuticals Plc | 27.01M |
| Jazz Pharmaceuticals Plc | 207.50M |
| Eli Lilly & Co. | 3.819B |
| Perrigo Co. Plc | 23.70M |